Next Generation Rocklatan

Last updated: November 17, 2025
Sponsor: Alcon Research
Overall Status: Completed

Phase

2

Condition

Ocular Hypertension

Open Angle Glaucoma

Glaucoma

Treatment

Netarsudil 0.02% Ophthalmic Solution

Latanoprost 0.005% Ophthalmic Solution

Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution

Clinical Study ID

NCT06441643
GLR305-E001
  • Ages > 18
  • All Genders

Study Summary

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Eligibility Criteria

Inclusion

Stage 1 Key Inclusion Criteria;

  • Diagnosis of OAG or OHT in both eyes.

  • High unmedicated IOP measurements in the study eye as specified in the protocol.

  • Corrected visual acuity equal to or better than +1.0 logMAR (Snellen equivalentequal to or better than 20/200) in the study eye.

  • Other protocol-specified inclusion criteria may apply.

Stage 2 Key Inclusion Criteria:

  • Diagnosis of OAG or OHT in both eyes.

  • High unmedicated IOP measurements in the study eye as specified in the protocol.

  • Corrected visual acuity equal to or better than +0.7 logMAR (Snellen equivalentequal to or better than 20/100) in the study eye.

  • Other protocol-specified inclusion criteria may apply.

Exclusion

Stage 1 and Stage 2 Key Exclusion Criteria:

  • Current use of more than 2 ocular hypotensive medications within 30 days (eithereye).

  • Intraocular pressure greater than 36 millimeters mercury (mmHg) at Screening.

  • Glaucoma other than OAG.

  • Previous glaucoma surgery.

  • Any abnormality preventing reliable measurements.

  • Unable to demonstrate proper eyedrop instillation.

  • Other protocol-specified exclusion criteria may apply.

Study Design

Total Participants: 426
Treatment Group(s): 6
Primary Treatment: Netarsudil 0.02% Ophthalmic Solution
Phase: 2
Study Start date:
September 04, 2024
Estimated Completion Date:
November 14, 2025

Study Description

During Stage 1, approximately 100 adult subjects with OAG or OHT will be randomized to 5 arms: 3 different concentrations of AR-17043, placebo comparator, or netarsudil 0.02% (Rhopressa®) for a treatment duration of 7 days.

During Stage 2, approximately 350 adult subjects with OAG or OHT will be randomized to 5 arms: low and high concentrations of PG043 (AR-17043/latanoprost 0.005%), AR-17043 high concentration, latanoprost, or netarsudil 0.02%/latanoprost 0.005% (Rocklatan®) for a treatment duration of 28 days.

Connect with a study center

  • Orange County Ophthalmology Medical Group

    Garden Grove, California 92843
    United States

    Site Not Available

  • United Medical Research Institute

    Inglewood, California 90301
    United States

    Site Not Available

  • Eye Research Foundation

    Newport Beach, California 92663
    United States

    Site Not Available

  • North Bay Eye Associates

    Petaluma, California 94954
    United States

    Site Not Available

  • Orange County Ophthalmology Medical Group

    Garden Grove 5351515, California 5332921 92843
    United States

    Site Not Available

  • United Medical Research Institute

    Inglewood 5359488, California 5332921 90301
    United States

    Site Not Available

  • Eye Research Foundation

    Newport Beach 5376890, California 5332921 92663
    United States

    Site Not Available

  • North Bay Eye Associates

    Petaluma 5382232, California 5332921 94954
    United States

    Site Not Available

  • Eye Center of Northern Colorado, PC

    Fort Collins, Colorado 80528
    United States

    Site Not Available

  • Eye Center of Northern Colorado, PC

    Fort Collins 5577147, Colorado 5417618 80528
    United States

    Site Not Available

  • Coastal Research Associates

    Roswell, Georgia 30076
    United States

    Site Not Available

  • Coastal Research Associates

    Roswell 4219934, Georgia 4197000 30076
    United States

    Site Not Available

  • Rochester Ophthalmological Group

    Rochester, New York 14618
    United States

    Site Not Available

  • Rochester Ophthalmological Group

    Rochester 5134086, New York 5128638 14618
    United States

    Site Not Available

  • James D. Branch Ophthalmology

    Winston-Salem, North Carolina 27101
    United States

    Site Not Available

  • James D. Branch Ophthalmology

    Winston-Salem 4499612, North Carolina 4482348 27101
    United States

    Site Not Available

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania 16066
    United States

    Site Not Available

  • Scott & Christie and Associates, PC

    Cranberry Township 8643098, Pennsylvania 6254927 16066
    United States

    Site Not Available

  • University Eye Specialists

    Maryville, Tennessee 37803
    United States

    Site Not Available

  • Total Eye Care PA

    Memphis, Tennessee 38119
    United States

    Site Not Available

  • University Eye Specialists

    Maryville 4639848, Tennessee 4662168 37803
    United States

    Site Not Available

  • Total Eye Care PA

    Memphis 4641239, Tennessee 4662168 38119
    United States

    Site Not Available

  • Piedmont Eye Center

    Lynchburg, Virginia 24502
    United States

    Site Not Available

  • Piedmont Eye Center

    Lynchburg 4771075, Virginia 6254928 24502
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.